首页 | 本学科首页   官方微博 | 高级检索  
检索        

基于病症条件的中药配伍禁忌毒效表征研究思路与方法
引用本文:庄朋伟,卢志强,孙凤姣,宋甜甜,张腾,吴锦,黄莹莹,张艳军.基于病症条件的中药配伍禁忌毒效表征研究思路与方法[J].中草药,2016,47(5):701-706.
作者姓名:庄朋伟  卢志强  孙凤姣  宋甜甜  张腾  吴锦  黄莹莹  张艳军
作者单位:天津中医药大学 天津市现代中药重点实验室, 天津 300193;天津中医药大学 天津市现代中药重点实验室, 天津 300193;天津中医药大学 天津市现代中药重点实验室, 天津 300193;天津中医药大学 天津市现代中药重点实验室, 天津 300193;天津中医药大学 天津市现代中药重点实验室, 天津 300193;天津中医药大学 天津市现代中药重点实验室, 天津 300193;天津中医药大学 天津市现代中药重点实验室, 天津 300193;天津中医药大学 天津市现代中药重点实验室, 天津 300193
基金项目:国家重点基础研究发展计划(2011CB505300,2011CB505302)
摘    要:中药配伍禁忌历来是中药安全性研究的重要科学问题之一。以"十八反"为代表,从安全性评价、毒效物质、毒理毒代、药物相互作用、毒性机制等方面,我国学者对中药配伍禁忌进行过大量研究,但是由于在研究思路、研究模式、研究方法等方面缺乏系统的设计和持续深入,许多关键问题尚缺乏可靠结论,未在学科、行业内达成共识。基于"半娄贝蔹及攻乌"配伍禁忌毒效表征基础研究,发现配伍禁忌相关反药组合在功效发挥过程中引起的严重不良反应是中药配伍禁忌"毒性"的主要表现。中药配伍禁忌的形成具有条件性,与其组成配比、剂量、配伍环境等要素密切相关,其中病症条件是配伍禁忌的关键影响因素,提出了基于病症条件的中药配伍禁忌毒效表征研究模式,为中药毒与效的整合分析研究提供了新的策略和方法学参考。

关 键 词:中药配伍禁忌  病症条件  毒效表征  十八反  研究模式
收稿时间:2/4/2016 12:00:00 AM

Methodology of toxicity-effect characterization of Chinese materia incompatibility based on disease and symptom conditions
ZHUANG Peng-wei,LU Zhi-qiang,SUN Feng-jiao,SONG Tian-tian,ZHANG Teng,WU Jin,HUANG Ying-ying and ZHANG Yan-jun.Methodology of toxicity-effect characterization of Chinese materia incompatibility based on disease and symptom conditions[J].Chinese Traditional and Herbal Drugs,2016,47(5):701-706.
Authors:ZHUANG Peng-wei  LU Zhi-qiang  SUN Feng-jiao  SONG Tian-tian  ZHANG Teng  WU Jin  HUANG Ying-ying and ZHANG Yan-jun
Institution:Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China;Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China;Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China;Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China;Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China;Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China;Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China;Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
Abstract:The incompatibility of Chinese materia medica(CMM) has always been one of the important scientific issues of CMM safety research. Extensive researches about CMM incompatibility have been carried out represented by "eighteen-antagonisms", mainly focused on the safety evaluation, toxic effects of substances, toxicology, toxicokinetics, drug interactions, toxicity mechanisms, etc. However, due to lack of system design on research ideas, model and methods, many key issues still lacked reliable conclusions, and did not reach a consensus within the industry. We completed the toxicity-effect characterization of the anti-drugs about "Pinelliae Rhizoma, Trichosanthis Fructus, Fritillariae Cirrhosae Bulbus, Ampelopsis Radix, and Bletillae Rhizoma attack Aconiti Radix" and proposed that the serious adverse reactions caused by related anti-drug combination therapy were because of the "toxicity" of CMM incompatibility. The formation of CMM incompatibility was closely related to its composition, dose, compatibility environment, etc, wherein the disease and symptom are the key factors of incompatibility. Eventually, the research model of toxicity-effect characterization of CMM incompatibility based on the desease and symptom was formed, it was viable to provide new strategies and methods for the clinical drug safety of CMM compatibility.
Keywords:Chinese materia medica incompatibility  desease and symptom  toxicity-effect characterization  eighteen-antagonisms  research model
本文献已被 CNKI 等数据库收录!
点击此处可从《中草药》浏览原始摘要信息
点击此处可从《中草药》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号